α galactosylceramide

C16 Galactosylceramide is a sphingolipid compound involved in lipid metabolism and immune modulation within cells. It is applicable in research related to diabetes and other conditions.

C16 3'-sulfo galactosylceramide (d18:1/16:0) is a sulfated glycolipid. C16 3'-sulfo galactosylceramide (d18:1/16:0) is a relatively abundant sulfide found in porcine brain and plasma that decreases throughout development in mice. C16 3'-sulfo galactosylceramide (d18:1/16:0) is a relatively abundant sulfide found in porcine brain and plasma that decreases throughout development in mice. C16 3'-sulfo galactosylceramide (d18:1/16:0) is a relatively abundant sulfide found in porcine brain and plasma that decreases throughout development in mice. C16 3'-sulfo galactosylceramide (d18:1/16:0) inhibits retinal ganglion cell growth in vitro. C16 3'-sulfo galactosylceramide (d18:1/16:0) has been used as an internal standard for quantifying C16 3'-sulfo galactosylceramide (d18:1/16:0) in rat cerebellum and white matter isolated from patients with multiple sclerosis. reference for sulphides.

C24:1 3'-sulfo galactosylceramide (d18:1/24:1(15z)) is the predominant sulfate analog in the mature myelin sheath. C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) interacted with C-type lectin and immunoglobulin-like receptors to give the highest affinity for LMIR5. Galactosylceramide (d18:1/24:1(15Z)) induces MCP-1 production by basophils, which activates NFAT by increasing LMIR5, but not mast cells .C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) binds in vitro to CD1d binding and increased the proliferation of free mouse splenocytes.

C12 3'-sulfo Galactosylceramide (d18:1/12:0) is a lipid molecule that can be used in life science related research. The CAS number of C12 3'-sulfo Galactosylceramide (d18:1/12:0) is 852100-88-0.

C19 3'-Sulfo Galactosylceramide (d18:1/19:0) is a synthetic derivative of sulfoglycolipids.

α-Galactosylceramide (KRN7000) is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo. It also activates NF-κB production in C6 glioma cells when used at a concentration of 10 μM.

C12 Galactosylceramide is a bioactive sphingolipid. It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM. C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy. It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus.

C2 Adamantanyl Galactosylceramide (d18:1/2:0) (AdaGalCer) is a bioactive sphingolipid. It reduces globotriaosylceramide 3 synthesis from exogenous lactosylceramide in microsomes. AdaGalCer stimulates recombinant glucocerebrosidase activity in a pH-dependent manner. It activates glucocerebrosidase to decrease glucosylceramide accumulation in fibroblasts and lymphoblasts isolated from patients with Gaucher and Fabry disease, respectively.

C16 Galactosylceramide is a glycosphingolipid that contains a galactose moiety attached to a ceramide acylated with palmitic acid .

C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. Levels of short-chain sulfatides, including C18 3'-sulfo galactosylceramide, decrease with age in mice and humans. It is increased in brain from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions. Plasma levels of C18 3'-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale. It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).

C18:1 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been found in mouse brain. It has been used as a standard for the quantification of C18:1 3'-sulfo galactosylceramide in dried blood spots from patients with metachromatic leukodystrophy (MLD) by UPLC-MS.

C2 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been used as an internal standard in the quantification of lysosulfatides in mouse brain tissue and plasma.

C22 Galactosylceramide is a sphingolipid that has been found in the central nervous system.1,2C22 Galactosylceramide levels are increased in the spinal cord, but not the brain or liver, of mice fed a methionine-restricted diet.1C22 Galactosylceramide has been found in postmortem hippocampus from patients with Alzheimer's disease.2[Matreya, LLC.]

Tetracosanoyl-sulfatide is an endogenous sulfated glycolipid, which are also known as sulfatides . Tetracosanoyl-sulfatide is the major sulfatide in mature myelin in the central and peripheral nervous systems. Levels of Tetracosanoyl-sulfatide are elevated in plasma derived from patients with metachromatic leukodystrophy, a disorder characterized by arylsulfatase A deficiency, leading to sulfatide accumulation. Unlike C24:1 3'-sulfo galactosylceramide, it does not induce an immune response in mouse splenocytes in vitro.

N-Acetylpsychosine, also known as α-galactosylated C2-ceramide (d18:1/2:0), exhibits immunostimulatory properties. This compound, N-Acetylpsychosine, holds potential as a valuable tool for studying the mechanisms of apoptosis and immune responses activated by dendritic cells (DCs).

α-Galactosylceramide analog 8 (α-GalCer analog 8) is a triazole derivative of α-galactosylceramide. [1] It increases IL-2 secretion by DN32.D3 NKT hybridoma cells when co-cultured with CD1d-transfected RBL cells pre-loaded with α-GalCer analog 8 at a concentration of 32 ng/ml. α-GalCer analog 8 (32 ng/ml) induces IL-4 secretion to a greater extent than the synthetic α-GalCer KRN 7000 in mouse splenocytes in vitro and in mouse serum following administration of a 1 µg per animal dose, indicating a Th2 response.

KBC-007 is a synthetic branched chain-containing analog of α-galactosylceramide (α-GalCer). It induces IL-4 and IFN-γ secretion by mouse splenocytes when used at a concentration of 0.5 ng/ml and IL-2 secretion by DN32.D3 NKT hybridoma cells co-cultured with CD1d-transfected RBL cells pre-loaded with KBC-007 at a concentration of 8 ng/ml. KBC-007 (1 μg per animal) increases levels of IL-4, but not IFN-γ, to a similar degree as α-GalCer in mouse serum. KBC-007 (0.5 μg per animal) increases the survival rate of mice immunized with the inactivated influenza A virus A/PR/8/34 in a model of influenza infection.

αGalCer-RBD, a conjugate of the potent invariant natural killer T cell (iNKT) agonist α-Galactosylceramide (αGalCer) and the receptor-binding domain (RBD), serves as a self-adjuvanting lipoprotein that exhibits strong potential as a COVID-19 vaccine candidate. This compound effectively induces immunity against SARS-CoV-2 and its variants of concern by promoting the development of RBD-specific, cytokine-producing T cells.